No Data
No Data
Express News | Aquestive Therapeutics Reiterates Expected Timing For Anaphylm NDA Filing For Q1 2025
Express News | Aquestive Therapeutics : Reiterates Expected Timing for Filing Nda for Anaphylm Sublingual Film to FDA in Q1 of 2025
Express News | Aquestive Therapeutics Comments on Recent FDA Approval of Non-Injection-Based Epinephrine Product for the Treatment of Anaphylaxis and Reiterates Expected Timing for Nda Filing of Anaphylm™
Buy Rating Affirmed for Aquestive Therapeutics as Anaphylm Poised to Transform Epinephrine Market
H.C. Wainwright Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $9
Raymond James Ups ARS to Strong Buy, Cites FDA Neffy Approval
Lnova : Oh wow big news thank you for sharing